Renovaro Announces $15 million in Equity Committed

Group 1 - Renovaro Inc. has secured $15 million in additional equity at a price of$1.00 per share, along with a privately placed cash warrant exercisable at $1.50 with a one-year term [1] - The CEO of Renovaro, David Weinstein, stated that the new capital will enable the company to accelerate its focus on revolutionizing healthcare through advanced diagnostics and personalized immunotherapy [2] - Renovaro aims to enhance precision and personalized medicine for longevity by integrating AI and biotechnology platforms for early diagnosis, targeted treatments, and drug discovery [2] Group 2 - Renovaro includes RenovaroBio, which specializes in advanced cell-gene immunotherapy, and RenovaroCube, which utilizes AI for multi-omic diagnostics and drug development [2]